Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo

Kun Huang Yan, Yung Wei Lin, Chi Hao Hsiao, Yu-Ching Wen, Ke Hsun Lin, Chung Chi Liu, Mao-Chih Hsieh, Chih Jung Yao, Ming De Yan, Gi Ming Lai, Shuang En Chuang, Liang Ming Lee

研究成果: 雜誌貢獻文章

11 引文 (Scopus)

摘要

Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'-dichlorofluorescein-diacetate (DCFH-DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through nonapoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.
原文英語
頁(從 - 到)1567-1571
頁數5
期刊Oncology Letters
5
發行號5
DOIs
出版狀態已發佈 - 十月 2013

指紋

Mefloquine
Prostatic Neoplasms
Cell Death
lissamine rhodamine B
Reactive Oxygen Species
Staining and Labeling
G1 Phase Cell Cycle Checkpoints
Trypan Blue
Propidium
Annexin A5
Cyclin D1
Malaria
Cause of Death
Cell Survival
Oxidative Stress
Up-Regulation
Control Groups

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

引用此文

Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo. / Yan, Kun Huang; Lin, Yung Wei; Hsiao, Chi Hao; Wen, Yu-Ching; Lin, Ke Hsun; Liu, Chung Chi; Hsieh, Mao-Chih; Yao, Chih Jung; Yan, Ming De; Lai, Gi Ming; Chuang, Shuang En; Lee, Liang Ming.

於: Oncology Letters, 卷 5, 編號 5, 10.2013, p. 1567-1571.

研究成果: 雜誌貢獻文章

Yan, Kun Huang ; Lin, Yung Wei ; Hsiao, Chi Hao ; Wen, Yu-Ching ; Lin, Ke Hsun ; Liu, Chung Chi ; Hsieh, Mao-Chih ; Yao, Chih Jung ; Yan, Ming De ; Lai, Gi Ming ; Chuang, Shuang En ; Lee, Liang Ming. / Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo. 於: Oncology Letters. 2013 ; 卷 5, 編號 5. 頁 1567-1571.
@article{ade861a415f14fd78f8ddbb9ad59c3f1,
title = "Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo",
abstract = "Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'-dichlorofluorescein-diacetate (DCFH-DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through nonapoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.",
keywords = "Glutathione, Mefloquine, Prostate cancer, Reactive oxygen species",
author = "Yan, {Kun Huang} and Lin, {Yung Wei} and Hsiao, {Chi Hao} and Yu-Ching Wen and Lin, {Ke Hsun} and Liu, {Chung Chi} and Mao-Chih Hsieh and Yao, {Chih Jung} and Yan, {Ming De} and Lai, {Gi Ming} and Chuang, {Shuang En} and Lee, {Liang Ming}",
year = "2013",
month = "10",
doi = "10.3892/ol.2013.1259",
language = "English",
volume = "5",
pages = "1567--1571",
journal = "Oncology Letters",
issn = "1792-1074",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Mefloquine induces cell death in prostate cancer cells and provides a potential novel treatment strategy in vivo

AU - Yan, Kun Huang

AU - Lin, Yung Wei

AU - Hsiao, Chi Hao

AU - Wen, Yu-Ching

AU - Lin, Ke Hsun

AU - Liu, Chung Chi

AU - Hsieh, Mao-Chih

AU - Yao, Chih Jung

AU - Yan, Ming De

AU - Lai, Gi Ming

AU - Chuang, Shuang En

AU - Lee, Liang Ming

PY - 2013/10

Y1 - 2013/10

N2 - Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'-dichlorofluorescein-diacetate (DCFH-DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through nonapoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.

AB - Mefloquine (MQ) is currently in clinical use as a prophylactic treatment for malaria. Previous studies have shown that MQ induces oxidative stress in vitro. The present study investigated the anticancer effects of MQ treatment in PC3 cells. The cell viability was evaluated using sulphorhodamine-B (SRB) staining, while annexin V and propidium iodide (PI) were used as an assay for cell death. Reactive oxygen species (ROS) formation was detected with 2',7'-dichlorofluorescein-diacetate (DCFH-DA), a sensitive intracellular probe, and the alteration of cellular status was defined by trypan blue staining. The results of the present study indicated that MQ has a high cytotoxicity that causes cell death in PC3 cells. MQ markedly inhibited the PC3 cells through nonapoptotic cell death. MQ also induced significant ROS production. The MQ treatment mediated G1 cell cycle arrest and cyclin D1 accumulation through p21 upregulation in the PC3 cells. Moreover, the use of MQ improved the survival of the treatment group compared with the control group in the experimental mice. The present study indicates that MQ possesses potential therapeutic efficacy for the treatment of prostate cancer (PCa) in vivo. These findings provide insights that may aid the further optimization and application of new and existing therapeutic options.

KW - Glutathione

KW - Mefloquine

KW - Prostate cancer

KW - Reactive oxygen species

UR - http://www.scopus.com/inward/record.url?scp=84875716471&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875716471&partnerID=8YFLogxK

U2 - 10.3892/ol.2013.1259

DO - 10.3892/ol.2013.1259

M3 - Article

AN - SCOPUS:84875716471

VL - 5

SP - 1567

EP - 1571

JO - Oncology Letters

JF - Oncology Letters

SN - 1792-1074

IS - 5

ER -